| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| systematic review | Q1504425 |
| review article | Q7318358 |
| P50 | author | Jouko Miettunen | Q38640161 |
| John J. McGrath | Q39061421 | ||
| Noora Hirvonen | Q58663049 | ||
| P2093 | author name string | Sukanta Saha | |
| Erika Jääskeläinen | |||
| Juha Veijola | |||
| Matti Isohanni | |||
| Pauliina Juola | |||
| P2860 | cites work | The promise of early intervention | Q37847196 |
| Cross-national clinical and functional remission rates: Worldwide Schizophrenia Outpatient Health Outcomes (W-SOHO) study | Q39048817 | ||
| European long-term followup studies of schizophrenia | Q39556698 | ||
| A selective review of recent North American long-term followup studies of schizophrenia | Q39556703 | ||
| Differential outcome of schizophrenia: where we are and where we would like to be. | Q43642710 | ||
| The International Pilot Study of Schizophrenia: five-year follow-up findings | Q44096741 | ||
| Modelling disease frequency measures in schizophrenia epidemiology | Q44199680 | ||
| One hundred years of schizophrenia: a meta-analysis of the outcome literature. | Q52882885 | ||
| Five-year clinical course and outcome of schizophrenia in Ethiopia | Q82612972 | ||
| The concepts of remission and recovery in schizophrenia | Q83343210 | ||
| A systematic review of the prevalence of schizophrenia | Q21144720 | ||
| A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology | Q21245281 | ||
| Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q21562278 | ||
| Recovery from psychotic illness: a 15- and 25-year international follow-up study | Q22241700 | ||
| Questioning an axiom: better prognosis for schizophrenia in the developing world? | Q22242830 | ||
| A systematic review of longitudinal outcome studies of first-episode psychosis | Q22251390 | ||
| A Systematic Review of Mortality in Schizophrenia | Q22253025 | ||
| Measuring inconsistency in meta-analyses | Q27860655 | ||
| Sex differences in schizophrenia, a review of the literature | Q33908820 | ||
| Remission in schizophrenia: proposed criteria and rationale for consensus | Q33985442 | ||
| Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis | Q33990440 | ||
| Long-term outcome of patients with schizophrenia: a review | Q33993701 | ||
| Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study | Q34003858 | ||
| Early intervention services, cognitive-behavioural therapy and family intervention in early psychosis: systematic review | Q34253069 | ||
| EPPIC: an evolving system of early detection and optimal management | Q34394702 | ||
| Recovery from schizophrenia: a concept in search of research | Q34424340 | ||
| Standardized remission criteria in schizophrenia. | Q34486075 | ||
| Schizophrenia: a concise overview of incidence, prevalence, and mortality | Q34778618 | ||
| The Natural Course of Schizophrenia: A Review of First-admission Studies | Q36279547 | ||
| The concepts of remission and recovery in schizophrenia | Q36582424 | ||
| What did the WHO studies really find? | Q37076239 | ||
| Dissecting the heterogeneity of schizophrenia outcomes | Q37076273 | ||
| Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept? | Q37137026 | ||
| Definitions of the term 'recovered' in schizophrenia and other disorders | Q37204681 | ||
| The relationship between the duration of untreated psychosis and outcome in low-and-middle income countries: a systematic review and meta analysis. | Q37398284 | ||
| Redefining outcome measures in schizophrenia: integrating social and clinical parameters | Q37670607 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| meta-analysis | Q815382 | ||
| systematic review | Q1504425 | ||
| P304 | page(s) | 1296-1306 | |
| P577 | publication date | 2012-11-20 | |
| P1433 | published in | Schizophrenia Bulletin | Q4049133 |
| P1476 | title | A systematic review and meta-analysis of recovery in schizophrenia | |
| P478 | volume | 39 |
| Q37306415 | "Everyone Needs a Friend Sometimes" - Social Predictors of Long-Term Remission In First Episode Psychosis |
| Q89970770 | "The Italian Study on Recovery 2" Phase 1: Psychometric Properties of the Recovery Assessment Scale (RAS), Italian Validation of the Recovery Assessment Scale |
| Q89964522 | A Multicenter Phase II RCT to Compare the Effectiveness of EMDR Versus TAU in Patients With a First-Episode Psychosis and Psychological Trauma: A Protocol Design |
| Q90638778 | A Multimodal Speech-Gesture Training Intervention for Patients With Schizophrenia and Its Neural Underpinnings - the Study Protocol of a Randomized Controlled Pilot Trial |
| Q61447979 | A randomized controlled trial of cognitive remediation for a national cohort of forensic patients with schizophrenia or schizoaffective disorder |
| Q47688150 | Achieving recovery in patients with schizophrenia through psychosocial interventions: A retrospective study |
| Q52645449 | Adjunctive nutrients in first-episode psychosis: A systematic review of efficacy, tolerability and neurobiological mechanisms. |
| Q39267126 | Age at onset and the outcomes of schizophrenia: A systematic review and meta-analysis |
| Q38759421 | Altering the course of schizophrenia: progress and perspectives |
| Q47891971 | Anticholinergic burden in schizophrenia and ability to benefit from psychosocial treatment programmes: a 3-year prospective cohort study |
| Q37609168 | Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis |
| Q38704394 | Antipsychotic combinations for schizophrenia. |
| Q39348889 | Antipsychotic combinations in schizophrenia |
| Q47697316 | Antipsychotic treatment: experiences of fully recovered service users |
| Q91238989 | Are shame and self-criticism the path to the pervasive effect of social stress reactivity on social functioning in psychosis? |
| Q57825253 | Are structural brain changes in schizophrenia related to antipsychotic medication? A narrative review of the evidence from a clinical perspective |
| Q90116242 | Are we getting any better at staying better? The long view on relapse and recovery in first episode nonaffective psychosis and schizophrenia |
| Q92861680 | Aripiprazole Long-Acting Injection During First Episode Schizophrenia-An Exploratory Analysis |
| Q37248462 | Association between Global Assessment of Functioning scores and indicators of functioning, severity, and prognosis in first-time schizophrenia |
| Q37698621 | Atypical antipsychotics: recent research findings and applications to clinical practice: Proceedings of a symposium presented at the 29th Annual European College of Neuropsychopharmacology Congress, 19 September 2016, Vienna, Austria |
| Q37635208 | Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis |
| Q35109168 | Clinical predictors of therapeutic response to antipsychotics in schizophrenia |
| Q90781276 | Clinical-learning versus machine-learning for transdiagnostic prediction of psychosis onset in individuals at-risk |
| Q40339770 | Co-morbid personality disorder in early intervention psychosis clients is associated with greater key worker emotional involvement. |
| Q34224025 | Cognition in schizophrenia: Past, present, and future |
| Q55333612 | Community-Based Psychosocial Treatment Has an Impact on Social Processing and Functional Outcome in Schizophrenia. |
| Q56957894 | Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis: A Systematic Review, Meta-analysis, and Meta-regression |
| Q30797835 | Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program |
| Q35162601 | Conceptualizing and contextualizing functioning in people with severe mental disorders in rural Ethiopia: a qualitative study |
| Q26745792 | Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia |
| Q28079821 | Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review |
| Q40095934 | Declining Clinical Course of Psychotic Disorders Over the Two Decades Following First Hospitalization: Evidence From the Suffolk County Mental Health Project |
| Q89862658 | Defining Treatment Response, Remission, Relapse, and Recovery in First-Episode Psychosis: A Survey among Korean Experts |
| Q90161450 | Determinants of clinical, functional and personal recovery for people with schizophrenia and other severe mental illnesses: A cross-sectional analysis |
| Q38868964 | Development and Validation of a Clinically Based Risk Calculator for the Transdiagnostic Prediction of Psychosis. |
| Q104478934 | Development and validation of multivariable prediction models of remission, recovery, and quality of life outcomes in people with first episode psychosis: a machine learning approach |
| Q37308704 | Diagnostic Stability of ICD/DSM First Episode Psychosis Diagnoses: Meta-analysis. |
| Q35450483 | Do negative symptoms of schizophrenia change over time? A meta-analysis of longitudinal data |
| Q22242820 | Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery? |
| Q47716191 | Does the Social Functioning Scale reflect real-life social functioning? An experience sampling study in patients with a non-affective psychotic disorder and healthy control individuals |
| Q52652401 | Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study. |
| Q26824516 | Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis |
| Q93128787 | Dynamic Interactive Social Cognition Training in Virtual Reality (DiSCoVR) for social cognition and social functioning in people with a psychotic disorder: study protocol for a multicenter randomized controlled trial |
| Q51735519 | Early Intervention and a Direction of Novel Therapeutics for the Improvement of Functional Outcomes in Schizophrenia: A Selective Review. |
| Q26471731 | Early interventions for prodromal stage of psychosis |
| Q92491482 | Early recovery in the first 24 months of treatment in first-episode schizophrenia-spectrum disorders |
| Q42400486 | Editorial: Non-pharmacological Interventions for Schizophrenia: How Much Can Be Achieved and How? |
| Q50625457 | Effectiveness and safety of clozapine in elderly patients with chronic resistant schizophrenia. |
| Q47565809 | Embracing Psychosis: A Cognitive Insight Intervention Improves Personal Narratives and Meaning-Making in Patients With Schizophrenia. |
| Q35843145 | Empirical evidence about recovery and mental health |
| Q92453407 | Epigenetic mechanisms in schizophrenia and other psychotic disorders: a systematic review of empirical human findings |
| Q38240604 | Family history of psychosis and social, occupational and global outcome in schizophrenia: a meta-analysis |
| Q99237658 | Feasibility and Efficacy of a Psychological Therapy for Patients With a Schizophrenic Psychosis in an Inpatient Setting: Study Protocol of a Randomized Switch Controlled Trial |
| Q47605577 | Flourishing With Psychosis: A Prospective Examination on the Interactions Between Clinical, Functional, and Personal Recovery Processes on Well-being Among Individuals with Schizophrenia Spectrum Disorders |
| Q57161745 | From Treatment Response to Recovery - a Realistic Goal in OCD |
| Q40710686 | Genome-wide association study of schizophrenia in Ashkenazi Jews. |
| Q57074410 | Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016 |
| Q38444551 | Glutamatergic agents for schizophrenia: current evidence and perspectives |
| Q47150301 | Health care use, drug treatment and comorbidity in patients with schizophrenia or non-affective psychosis in Sweden: a cross-sectional study |
| Q55252445 | Holistic Management of Schizophrenia Symptoms Using Pharmacological and Non-pharmacological Treatment. |
| Q95645291 | Impact of anticholinergic load on functioning and cognitive performances of persons with psychosis referred to psychosocial rehabilitation centers |
| Q41658737 | Improving outcomes of first-episode psychosis: an overview |
| Q36623546 | In-patient rehabilitation: clinical outcomes and cost implications |
| Q93069431 | Inefficient neural system stabilization: a theory of spontaneous resolutions and recurrent relapses in psychosis |
| Q99575601 | Inflammatory and Cardiometabolic Markers at Presentation with First Episode Psychosis and Long-term Clinical Outcomes: a longitudinal study using electronic health records |
| Q89572022 | Influence of More Than 5 Years of Continuous Exposure to Antipsychotics on Cerebral Functional Connectivity of Chronic Schizophrenia |
| Q35892576 | Influence of kynurenine 3-monooxygenase (KMO) gene polymorphism on cognitive function in schizophrenia |
| Q50230040 | Insight and recovery in schizophrenic patients |
| Q42052561 | Insights into psychosis risk from leukocyte microRNA expression |
| Q49952132 | Interplay Among Psychopathologic Variables, Personal Resources, Context-Related Factors, and Real-life Functioning in Individuals With Schizophrenia: A Network Analysis |
| Q60584643 | Intervention précoce pour la psychose : concepts, connaissances actuelles et orientations futures |
| Q36333281 | Investigating trajectories of social recovery in individuals with first-episode psychosis: a latent class growth analysis |
| Q55104225 | Is there compelling evidence that schizophrenia long-term treatment guidelines should be changed? |
| Q61817485 | Limited changes in activities of daily life performance ability among people with schizophrenia at clinical settings and the factors moderating the changes |
| Q111660895 | Mapping genomic loci implicates genes and synaptic biology in schizophrenia |
| Q30436393 | Mechanisms Underlying Auditory Hallucinations-Understanding Perception without Stimulus. |
| Q91942123 | Metacognitive Training Modulates Default-Mode Network Homogeneity During 8-Week Olanzapine Treatment in Patients With Schizophrenia |
| Q64238817 | Mobile Phone and Wearable Sensor-Based mHealth Approaches for Psychiatric Disorders and Symptoms: Systematic Review |
| Q39445777 | Multisite prediction of 4-week and 52-week treatment outcomes in patients with first-episode psychosis: a machine learning approach |
| Q90350386 | Neuropil contraction in relation to Complement C4 gene copy numbers in independent cohorts of adolescent-onset and young adult-onset schizophrenia patients-a pilot study |
| Q64903232 | Nonsocial and social cognition in schizophrenia: current evidence and future directions. |
| Q94235795 | Olanzapine dose for people with schizophrenia |
| Q34669624 | Omega-3 fatty acids in first-episode schizophrenia - a randomized controlled study of efficacy and relapse prevention (OFFER): rationale, design, and methods |
| Q35369948 | One-year randomized controlled trial and follow-up of integrated neurocognitive therapy for schizophrenia outpatients |
| Q37652248 | Outcomes following first-episode psychosis - Why we should intervene early in all ages, not only in youth. |
| Q38683538 | Oxytocin effects in schizophrenia: Reconciling mixed findings and moving forward |
| Q104073511 | Personalized estimates of morphometric similarity in bipolar disorder and schizophrenia |
| Q38654761 | Post-mortem molecular profiling of three psychiatric disorders |
| Q38836917 | Post-traumatic growth following a first episode of psychosis: a scoping review |
| Q39123249 | Prediction and prevention of psychosis: current progress and future tasks |
| Q42373625 | Prediction of Quality of Life in Asian Patients with Schizophrenia: A Cross-sectional Pilot Study. |
| Q35753980 | Prevalence of psychotic disorders in an urban area of France |
| Q94464218 | Proxy WHO Disability Assessment Schedule 2.0 Is Clinically Useful for Assessing Psychosocial Functioning in Severe Mental Illness |
| Q58775669 | Psychiatry's contribution to the public stereotype of schizophrenia: Historical considerations |
| Q96121305 | Psychometric Properties of the Brief Resilient Coping Scale in a Sample of Stable Severe Mental Disorder Patients |
| Q64105505 | Psychosis Polyrisk Score (PPS) for the Detection of Individuals At-Risk and the Prediction of Their Outcomes |
| Q97569733 | Reconceptualizing Psychosis: The Hearing Voices Movement and Social Approaches to Health |
| Q91379039 | Recover recovery style from psychosis: a psychometric evaluation of the German version of the Recovery Style Questionnaire (RSQ) |
| Q33836438 | Recovery and severe mental illness: description and analysis |
| Q48062610 | Recovery style and stigma in psychosis: the healing power of integrating. |
| Q42026249 | Recovery, not progressive deterioration, should be the expectation in schizophrenia |
| Q39403472 | Rehabilitation Interventions to Promote Recovery from Schizophrenia: A Systematic Review |
| Q101454070 | Rejoinder to commentary |
| Q104511204 | Rejoinder to rejoinder to commentary |
| Q98943930 | Risk factors of hospitalization for any medical condition among patients with prior emergency department visits for mental health conditions |
| Q38815462 | Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders |
| Q56959104 | Schizophrenia |
| Q37727560 | Schizophrenia--time to commit to policy change |
| Q89863912 | Self-stigma in serious mental illness and autism spectrum disorder: Results from the REHABase national psychiatric rehabilitation cohort |
| Q35709035 | Skating on thin ice: pragmatic prescribing for medication refractory schizophrenia |
| Q47318894 | Social Recovery Therapy in improving activity and social outcomes in early psychosis: Current evidence and longer term outcomes |
| Q102070559 | Stigma resistance is associated with advanced stages of personal recovery in serious mental illness patients enrolled in psychiatric rehabilitation |
| Q89748024 | Structural and functional imaging markers for susceptibility to psychosis |
| Q36246819 | Supplementation of Antipsychotic Treatment with the Amino Acid Sarcosine Influences Proton Magnetic Resonance Spectroscopy Parameters in Left Frontal White Matter in Patients with Schizophrenia |
| Q41658764 | Taking a Bleulerian perspective: a role for negative symptoms in the staging model? |
| Q36686443 | Targeting Treatment-Resistant Auditory Verbal Hallucinations in Schizophrenia with fMRI-Based Neurofeedback - Exploring Different Cases of Schizophrenia |
| Q64093332 | The 10-year functional outcome of schizophrenia in Butajira, Ethiopia |
| Q59052397 | The Concept of Schizophrenia: From Unity to Diversity |
| Q64070254 | The Implementation of Evidence-Based Psychiatric Rehabilitation: Challenges and Opportunities for Mental Health Services |
| Q55024304 | The Importance of Social Cognition in Improving Functional Outcomes in Schizophrenia. |
| Q38399111 | The RAISE early treatment program for first-episode psychosis: background, rationale, and study design |
| Q57741700 | The central role of self-agency in clinical recovery from first episode psychosis |
| Q94484027 | The clinical course of schizophrenia in women and men-a nation-wide cohort study |
| Q40077879 | The differential effects of a focus on symptoms versus recovery in reducing stigma of schizophrenia. |
| Q93114715 | The effect of baseline antipsychotic status on the 12-month outcome in initially stabilized patients with schizophrenia |
| Q38234436 | The onset and offset of psychosis--and what happens in between--a commentary on ‘Reappraising the long-term course and outcome of psychotic disorders: the AESOP-10 Study’ by Morgan et al. (2014). |
| Q96773916 | The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia |
| Q47945243 | The slow death of the concept of schizophrenia and the painful birth of the psychosis spectrum. |
| Q39002140 | The treatment of schizophrenia: Can we raise the standard of care? |
| Q38718345 | Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries |
| Q38279578 | Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics |
| Q60441606 | Treatment resistant schizophrenia – review and a call to action |
| Q35673737 | Twenty Years of Schizophrenia Research in the Northern Finland Birth Cohort 1966: A Systematic Review |
| Q64448881 | Using Twitter to assess attitudes to schizophrenia and psychosis |
| Q55023835 | What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? |
| Q60314538 | fMRI correlates of jumping-to-conclusions in patients with delusions: Connectivity patterns and effects of metacognitive training |
Search more.